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Abstract
Background: Dipeptidyl peptidase-IV (DPP-IV) is suggested to contribute to the pathogenesis of several
autoimmune diseases. The aim of this study was to evaluate the association of DPP-IV presence in blood plasma
and mononuclear cells with the disease activity in rheumatoid arthritis (RA).
Methods: Patients with active RA (n = 27) were examined at the study enrolment and a follow-up examination was
performed after the regression of the joint effusions and at least 6 months after the first investigation. The control
group comprised patients with a noninflammatory joint disease, i.e. osteoarthritis (OA; n = 15). The DPP-IV-like
enzymatic activity was measured by a kinetic fluorimetric method, the concentration of DPP-IV in the blood plasma
was determined using ELISA and the expression of DPP-IV in leukocytes was assayed by flow cytometry.
Results: Blood plasma DPP-IV-like enzymatic activity (median ± SD 220.15 ± 83.6 pkat/mL in RA vs. 376.9 ± 144.9
pkat/mL in OA, p < 0.001) and concentrations (median ± SD 465.1 ± 215.6 ng/mL in RA vs. 953.3 ± 368.4 ng/mL in
OA, p < 0.001) were lower in patients with active RA compared to OA. In RA patients, the blood plasma DPP-IV-like
enzymatic activity negatively correlated with the CRP concentration (r = −0.39, p = 0.044). No significant differences
were observed in the DPP-IV-like enzymatic activity and DPP-IV expression in blood mononuclear cells between the
RA and OA groups. At follow-up, 18 RA patients had a less active disease as demonstrated by an improved DAS28
score. In this group, comparison of the entry and the follow-up values in individual patients revealed an increase of
the blood plasma DPP-IV-like enzymatic activity (median ± SD 141 ± 46 % of the patient’s entry values, p = 0.011)
and DPP-IV concentration (median ± SD 168 ± 25 %, of the patient’s entry values, p = 0.033). In contrast to the
blood plasma, the DPP-IV expression in blood mononuclear cells was reduced in these patients as evidenced by
a decrease in the cell surface DPP-IV-like enzymatic activity as well as the median fluorescence intensity of
DPP-IV staining in lymphocytes (median ± SD 66 ± 56 %, p = 0.018 and 63 ± 31 % of the patient’s entry values,
p = 0.005, respectively).
Conclusions: The association between RA activity and the changes in blood plasma and blood mononuclear
cell DPP-IV in individual patients supports the possible relationship of DPP-IV to RA pathophysiology.
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Background
Dipeptidyl peptidase-IV (DPP-IV, CD26, EC 3.4.14.5) is a
plasma membrane peptidase that selectively cleaves an N-
terminal dipeptide from peptides with a proline or alanine
residue in the penultimate position. DPP-IV is widely
expressed on epithelial and endothelial cells and a soluble
form can be found in body fluids including blood plasma,
where it represents at least 95 % of the DPP-IV-like en-
zymatic activity [1]. In the immune system, DPP-IV is
expressed preferentially by the CD4+CD45RO+ memory
T cells, is associated with the Th1 response and its expres-
sion is upregulated following T cell activation [2, 3]. In
contrast, DPP-IV is low or undetectable on B-cells, NK
cells and monocytes in healthy adults [4]. DPP-IV is
well known as a T cell co-stimulatory molecule involved
in the T cell activation and proliferation [5]. Some of
the DPP-IV effects are executed by its hydrolytic activ-
ity (processing of cytokines, chemokines and neuropep-
tides), while some others are mediated by non-
hydrolytic interactions (adenosine deaminase binding,
interaction with the tyrosine-phosphatase CD45) [5–7].
In in vitro studies, some of the DPP-IV inhibitors were
demonstrated to suppress the production of various cy-
tokines and enhance the production of the suppressive
cytokine transforming growth factor beta [8].
Changes in the expression and/or the blood plasma
concentration of DPP-IV are associated with several dis-
eases including rheumatoid arthritis (RA) [5], an auto-
immune inflammatory disorder characterized by synovial
inflammation leading to cartilage destruction as well as
systemic manifestations. The pathogenesis of RA has not
been clearly elucidated so far, but involves an interplay
of predisposing genetic factors, sex hormones and pos-
sibly an infectious or another immunity triggering agent
that ultimately lead to an inappropriate activation of the
immune system and perpetuating inflammation [9].
Given the role of DPP-IV in T cell activation [10] and its
ability to cleave numerous proinflammatory peptides in-
volved in the pathogenesis of RA [5], several studies ex-
amined its possible significance in the disease progression.
The results of these studies, including ours, have so far re-
vealed (although variably) a decreased DPP-IV-like en-
zymatic activity in the mononuclear cells isolated from the
synovial fluid of RA patients [11, 12] as well as decreased
blood plasma DPP-IV enzymatic activity/concentration
[12–14]. Higher DPP-IV expression was reported in blood
mononuclear cells and especially CD4+ T lymphocytes in
RA patients with high disease activity compared to healthy
controls [15–18]. The literature data on the association of
these changes with the disease activity are inconsistent
[12, 14, 18, 19]. Furthermore, it is currently unclear
whether the changes of DPP-IV in blood plasma and per-
ipheral mononuclear cells relate to the disease activity on
the intraindividual basis.
Methods
27 patients with RA diagnosed according to the standard
criteria of the American College of Rheumatology were
examined during the active phase of their disease with
joint effusion (active RA), 15 patients with osteoarthritis
served as controls (Table 1). RA disease activity was
evaluated using the DAS28 score based on the blood
plasma concentration of the C-reactive protein (CRP),
patient-assessed visual analogue scale (VAS) and swollen
and tender joint counts (http://www.das-score.nl/). The
follow-up examination in RA patients was performed
after joint effusion regression and at least 6 months after
the first investigation. Intraindividual changes of the
studied parameters were evaluated in patients with at
least a moderate improvement of the disease activity as
defined by the change of the DAS28 score (a decrease in
DAS28 > 0.6 if the current value was <5.1 or a decrease
in DAS28 > 1.2 if the current value was >5.1). The
study was approved by the Institutional ethics commit-
tee of the Institute of Rheumatology in Prague under
the code EK-C327LS/06 and was conducted in accord-
ance with the Declaration of Helsinki. All patients
signed informed consent.
Peripheral blood was collected under sterile conditions
into BD Vacutainer (BD Biosciences, USA) with sodium
heparin as an anticoagulant. Blood mononuclear cells
(BMNC) were isolated by discontinuous Ficoll-Paque
density centrifugation in the “cell preparation tube” with
sodium heparin (CPT, BD Biosciences, USA). Isolated
BMNC were counted on a cell counter Z2 (Beckman
Coulter, USA); there were more than 95 % of viable cells
as determined by trypan blue exclusion.
The DPP-IV-like enzymatic activity in the heparinized
blood plasma and in BMNC was measured by a continu-
ous rate fluorimetric assay with 7-(glycyl-prolylamido)-
4-methylcoumarin (Bachem, Switzerland, final concen-
tration 50 μmol/L), as a substrate at pH 7.5 and 37 °C.






Age 59 ± 13 62 ± 11
Male/Female 7/20 6/9
Disease duration (years) 12.5 ± 12.4 –
Swollen joint counts (0–28) 9 ± 6.3 –
Tender joint counts (0–28) 11 ± 6.7 –
DAS 28 5.8 ± 1.1 –
ESR (mm/h) 56 ± 28.2 10 ± 6.4
CRP (mg/L) 44 ± 26 5 ± 4
DAS 28 Disease activity score, CRP C-reactive protein, ESR Erythrocyte
sedimentation rate. The values are medians ± SD
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The release of 7-amino-4-methylcoumarin was moni-
tored at excitation and emission wavelengths of 380 and
460 nm, respectively (Spectrofluorimeter Perkin Elmer
LS50B). The cell surface DPP-IV-like enzymatic activity
in BMNC was determined as the activity of viable cells,
the total DPP-IV-like enzymatic activity was measured
under the same conditions after permeabilization of the
cells with 0.1 % Triton X-100 [12].
Immunophenotypization of the BMNC was performed
by a flow cytometer FACS Canto (BD Biosciences, USA)
with the Diva software for acquisition and FlowJo
(TreeStar Inc.) for data evaluation. 50 μL of the peripheral
blood was incubated for 30 min at room temperature with
mouse anti-CD3-PerCP, anti-CD4-APC, anti-CD8-APC-
Cy7 and anti-CD14-PE-Cy7 (all from BD Biosciences), rat
anti-DPP-IV/CD26-FITC (RD systems). All antibodies were
used in the titre of 1:20. Lymphocyte subsets were iden-
tified by gating analysis and fluorescence profiles were
obtained for 10 000 cells in each sample. Median fluor-
escence intensity (MFI) of DPP-IV/CD26 expression in
lymphocytes was calculated as a ratio of the median
fluorescence intensity of the DPP-IV/CD26 positive and
negative lymphocyte populations.
Blood plasma DPP-IV concentration was determined
by the sandwich enzyme-linked immunosorbent assay
(“Duo set” ELISA kit – DY1180, RD Systems, UK), ac-
cording to the manufacturer’s instructions. A micro-
plate reader Sunrise (Tecan, Switzerland) was used to
measure the absorbance at 450 nm, a wavelength cor-
rection was performed at 570 nm.
The Statistica 12 software (StatSoft, Inc., USA) was
used for statistical analyses. The Wilcoxon pair test and
the Mann–Whitney U test were used as appropriate.
Correlations were analyzed by the Spearman’s correl-
ation coefficient.
Results
DPP-IV in patients with active rheumatoid arthritis
Compared to patients with osteoarthritis (OA), rheuma-
toid arthritis (RA) patients recruited in the active phase
of their disease exhibited significantly lower blood
plasma DPP-IV-like enzymatic activity (median ± SD
220.15 ± 83.6 pkat/mL in RA vs. 376.9 ± 144.9 pkat/mL
in OA, p < 0.001) and blood plasma DPP-IV concentra-
tion (median ± SD 465.1 ± 215.6 ng/mL in RA vs. 953.3
± 368.4 ng/mL in OA, p < 0.001) (Fig. 1). The blood
plasma DPP-IV-like enzymatic activity correlated with
DPP-IV concentration determined by ELISA (r = 0.83,
p < 0.001). In RA patients, there was a negative cor-
relation between the DPP-IV-like enzymatic activity
and the CRP concentration (Fig. 2). These results
were consistent with the previously published data,
including ours [5, 12, 20].
Neither the DPP-IV-like enzymatic activity in blood
mononuclear cells nor the DPP-IV expression in lympho-
cytes determined by flow cytometry were significantly dif-
ferent in patients with active RA compared to OA (data not
shown).
Intraindividual changes of DPP-IV in blood plasma and in
blood mononuclear cells parallel disease activity in RA
To evaluate whether the changes in the blood plasma
DPP-IV reflect disease activity in individual patients, a
follow-up evaluation was performed in 18 patients with
RA during a less active phase of their disease as defined
by the regression of joint effusion and improved DAS28
score compared to the entry values. The disease activity
decreased (Table 2) as evidenced by the reduction of the
markers of inflammation CRP and ESR. In 13 patients
(72 %), this improvement was associated with a rise of
DPP-IV-like enzymatic activity in the blood plasma of at
least 20 % compared to the individual patient’s entry
values. The enzymatic activity remained unchanged in 3
(17 %) and decreased in 2 (11 %) patients. Overall, the
blood plasma DPP-IV-like enzymatic activity rose to
141 ± 46 % (median ± SD, p = 0.011) compared to the
entry values of individual patients. A similar increase to
168 ± 25 % (median ± SD, p = 0.033) of the patient’s entry
values was observed for the blood plasma DPP-IV con-
centration as determined by ELISA. The changes of
Fig. 1 Blood plasma DPP-IV-like enzymatic activity and concentration in RA and OA patients. In the box plots, the medians are depicted as small
squares, interquartile range (25–75th centile) as boxes and bars extend from the minimum to maximum values. *p < 0.001, Mann–Whitney U test
Sromova et al. BMC Musculoskeletal Disorders  (2015) 16:244 Page 3 of 7
these parameters in individual patients are shown in
Fig. 3. Despite this observed increase of the blood
plasma DPP-IV, the median of the values in the RA pa-
tients in the less active state of the disease still remained
approximately 30 % below the levels in the OA patients
(data not shown), most likely due to the background of
the RA disease activity.
In contrast to the dynamics of the blood plasma DPP-
IV, an inverse trend was seen in the BMNC (Fig. 4). The
plasma membrane as well as the total DPP-IV-like
enzymatic activity in BMNC decreased to 66 ± 56 %
(median ± SD, p = 0.018) and 52 ± 64 % (p = 0.005),
respectively, of the entry values of individual patients.
Using flow cytometry, DPP-IV/CD26 was detected in
lymphocytes and only exceptionally a very low positivity
was observed in monocytes (data not shown). The per-
centage of CD26 positive lymphocytes was statistically
significantly decreased compared to the individual pa-
tient entry values (p = 0.029, data not shown). Larger
changes were observed in the quantity of DPP-IV/CD26
expression as determined by median fluorescence inten-
sity, which was decreased to 63 ± 31 % of the patient’s
entry values (median ± SD, p = 0.005).
Taken together, the attenuation of RA disease activity
was accompanied by a rise of the blood plasma DPP-IV
and a reduction of DPP-IV expression in BMNC in the
majority of patients. At a cut-off level of a 20 % change
in comparison to the entry values for DPP-IV enzymatic
activity, 45 % of the patients exhibited both of these
changes concurrently.
Discussion
Dipeptidyl peptidase-IV (CD26) is a T lymphocyte cost-
imulatory molecule and is also involved in the proteo-
lytic regulation of several proinflammatory mediators
[5]. Numerous studies have therefore explored the role
of DPP-IV in autoimmune and inflammatory diseases,
including systemic lupus erythematosus, multiple scler-
osis, inflammatory bowel disease and RA [14, 21–25].
Decreased DPP-IV in blood plasma in comparison with
healthy controls was described in patients with systemic
lupus erythematosus, inflammatory bowel disease and
multiple sclerosis [5, 23, 24, 26]. In contrast with blood
plasma, several authors found higher frequency of
DPP-IV positive blood cells compared to healthy
controls in inflammatory bowel disease and multiple
sclerosis patients [23, 25]. In addition, there was a cor-
relation of the frequency of CD4+DPP-IV high+ cells
with the clinical severity in patients with multiple scler-
osis [3, 26], while reduced levels of the DPP-IV expres-
sion in BMNC were observed in highly active systemic
lupus erythematosus [24].
RA patients exhibit lower blood plasma DPP-IV-like en-
zymatic activity compared to the controls [14, 20, 27, 28].
Patients with a noninflammatory joint disease (osteoarth-
ritis) were used as a control group in our current study.
r = -0.39 
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Fig. 2 Negative correlation between the blood plasma DPP-IV-like enzymatic activity and CRP concentration in RA patients. Spearman’s
correlation coefficient is shown
Table 2 Clinical characteristics of the RA patients exhibiting at
least moderate improvement at the follow-up examination
Entry values Follow-up
Age 60 ± 16 61 ± 16
Male/Female 5/13 5/13
Disease duration (year) 4.5 ± 13.3 5.5 ± 13.5
Swollen joint count (0–28) 9 ± 6 2 ± 3
Tender joint count (0–28) 11.5 ± 6.5 2.5 ± 6.6
DAS 28 5.66 ± 0.97 3.49 ± 1.22
ESR (mm/h) 56 ± 27.7 30 ± 24.1
CRP (mg/L) 51.08 ± 24.49 7.31 ± 19.13
DAS 28 Disease activity score, CRP C-reactive protein, ESR Erythrocyte
sedimentation rate. The values are medians ± SD
Sromova et al. BMC Musculoskeletal Disorders  (2015) 16:244 Page 4 of 7
We demonstrate that both the DPP-IV-like enzymatic ac-
tivity and DPP-IV concentration were almost 50 % lower
in RA compared to patients with osteoarthritis. Cuchacov-
ich et al. suggested that the decrease of DPP-IV enzymatic
activity in blood plasma may be a consequence of the
lower specific enzymatic activity of DPP-IV in RA pa-
tients compared to the healthy subjects caused by its
hypersialylation [29]. Our data in agreement with other
reports [13, 19, 20] show that the lower enzymatic
activity observed in RA patients is in large part caused
by the decreased blood plasma concentration of the
DPP-IV protein.
In our study, we observed neither a significant differ-
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Fig. 3 Blood plasma DPP-IV in RA patients with clinical improvement of the disease. Blood plasma DPP-IV-like enzymatic activity (n = 18) and
DPP-IV concentration (n = 13) were determined in patients exhibiting at least a moderate improvement of the disease, individual entry and




















































Fig. 4 DPP-IV in blood mononuclear cell (BMNC) in RA patients with clinical improvement of the disease. Cell surface DPP-IV-like enzymatic
activity (n = 18) and the median fluorescence intensity (MFI) of DPP-IV in lymphocytes (n = 14) were determined in patients exhibiting at least
a moderate improvement of the disease, individual entry and follow-up values are depicted. *p < 0.05, Wilcoxon pair test
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nor in the intensity of DPP-IV/CD26 expression in lym-
phocytes between RA and osteoarthritis patients. More-
over, the DPP-IV-like enzymatic activity in blood
mononuclear cells was similar in RA and OA patients
(data not shown), which was in line with our previously
published data on an independent patient cohort [12].
Increased DPP-IV/CD26 expression on blood mono-
nuclear cells of RA patients in comparison to healthy in-
dividuals was proposed by some authors. Muscat et al.
[15] suggested that higher RA disease activity was asso-
ciated with increased DPP-IV expression in peripheral
blood T cells, while patients with less active disease had
DPP-IV expression comparable to healthy subjects. In
addition, Ellingsen et al. observed a significant increase
of the DPP-IV/CD26 antigen expression in CD4+ T cells
only in patients with chronic (median disease duration
11.5 years) rheumatoid arthritis [16], while in RA pa-
tients early after diagnosis (<6 months), there were no
differences in comparison to healthy controls [30]. The
direct comparison of the so far published studies is
problematic due to the variance of the disease activity
typically occurring within the experimental groups as
well as different methodologies used for the disease ac-
tivity assessment, different control groups (osteoarthritis
patients vs. healthy individuals) and variable duration of
the illness.
Our previously published data showed a negative
correlation between the DPP-IV-like blood plasma enzym-
atic activity and CRP [12]. Cordero et al. [19] described
the inverse correlation between the blood serum DPP-IV
concentration and the number of swollen joints, but did
not observe differences in the blood serum DPP-IV con-
centration in the groups of patients with active as com-
pared to inactive RA. Similarly, Ulusoy et al. [13] did not
find a significant association between DPP-IV blood
serum concentration and RA disease activity. Higher ex-
pression of DPP-IV in T cells was detected in patients with
active RA as compared to the less active RA [15, 17]. The
main focus of our current study was to extend and
strengthen the so far available evidence of the association
of DPP-IV with the RA disease activity by analyzing the
intraindividual dynamics of DPP-IV associated with the
disease improvement. During our study, the patients
received various types of therapy based on the clinical
judgment of the attending physician (glucocorticoids,
methotrexate, anti-TNF alpha and anti-CD20 antibodies,
leflunomide, sulfasalazine and their combinations). Des-
pite this heterogeneity of the administered treatment, we
observed consistent and significant intraindividual in-
crease in the blood plasma DPP-IV enzymatic activity and
concentration in follow-up examinations in patients with
decreased RA activity. An increase of the DPP-IV enzym-
atic activity accompanied by a shift from acidic to more
neutral glycoforms of the circulating DPP-IV was
previously observed in RA patients with clinical improve-
ment after anti TNF alpha therapy [31].
In addition to the changes in the levels of the circulat-
ing DPP-IV, our study suggests that both the DPP-IV-
like enzymatic activity in BMNC and its expression in
lymphocytes are decreased along with an improvement
of the disease in individual patients. The intraindividual
decrease of the DPP-IV/CD26 antigen expression was
most notable in the CD4+ T cells (p = 0.055, data not
shown) which is in agreement with the reported domin-
ant presence of DPP-IV/CD26 in this lymphocyte sub-
population in RA patients [15].
The consistent increase of the plasma DPP-IV and the
decrease of the DPP-IV expression on T cells observed
in the majority of patients with the disease improvement
in our study suggest the role of DPP-IV in RA patho-
physiology. However, since we observed the simultan-
eous occurrence of both of these changes only in 45 %
of the improved patients, it remains currently unclear,
whether they are directly related to each other or
whether they are part of different biological processes
occurring during the disease improvement.
Limitations of the study
Although the effects of the administered treatment and
duration of the disease on the plasmatic and T cell DPP-
IV are largely unknown, the heterogeneity of our RA pa-
tient cohort with regard to these variables may represent
a possible limitation of our study.
Conclusions
Blood plasma DPP-IV enzymatic activity and concentra-
tion are lower in RA patients during the active phase of
the disease compared to the noninflammatory arthritis
(osteoarthritis) patients. In addition, our intraindividual
comparison demonstrates elevation of the blood plasma
DPP-IV and a decrease of DPP-IV/CD26 in peripheral
blood mononuclear cells associated with the clinical im-
provement in the majority of RA patients. These results
further support the possible role of DPP-IV in the
pathophysiology of RA.
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